Grifols is a global healthcare company founded in Barcelona in 1940, committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services in more than 100 countries.
As pioneers in the field of the plasma science, Grifols is one of the largest plasma companies, with a growing network of donation centers worldwide. It develops this plasma into essential medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. And the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.
In December 2018, Grifols began purifying plasma from healthy Ebola survivors from Liberia to produce anti-Ebola immunoglobulin, a potential treatment for patients affected by the Ebola virus in Africa, as part of a longer-term Grifols clinical research program. Grifols's work includes a first-of-its-kind modular plasma donation center that was deployed to Monrovia, Liberia. Grifols also constructed a dedicated processing facility at its Clayton manufacturing complex to produce anti-Ebola Immunoglobulin. The project is the result of collaborative efforts among Grifols, several non-profit organizations and Liberian scientists at the National Public Health Institute of Liberia. As part of the non-profit project, more than 40 Grifols employees and Probitas Foundation (a Grifols philanthropic organization) professionals traveled to Liberia for extended periods and volunteered in the plasma-collection process and community efforts.